Literature DB >> 1596681

Effect of murine recombinant interleukin-5 on the cell population in guinea-pig airways.

T Iwama1, H Nagai, H Suda, N Tsuruoka, A Koda.   

Abstract

1. An intratracheal injection of murine recombinant interleukin 5 (mrIL-5, 2-15 microgram/0.25 ml/animal) induced a dose-dependent increase in the number of macrophages, eosinophils, neutrophils and epithelial cells in the bronchoalveolar lavage fluid (BALF) of guinea-pigs 24 h after administration. Bovine serum albumin (15 micrograms/0.25 ml/animal), used as a reference material, did not cause any change of this type. 2. The intratracheal administration of mrIL-5 at a dose of 15 microgram showed a tendency to increase the number of these pulmonary inflammatory cells and epithelial cells in the BALF at 12 h with a significant increase observed at 24 h. 3. Prednisolone (20 mg kg-1, i.p.) inhibited the mrIL-5-induced increase in macrophages, eosinophils, neutrophils and epithelial cells. Ketotifen (2 mg kg-1, i.p.) reduced the mrIL-5-induced increase in the eosinophil, neutrophil and epithelial cell populations. The simultaneous injection of 2% disodium cromoglycate (DSCG) into the trachea prevented the mrIL-5-induced increase in the number of airway epithelial cells, without affecting changes in the other inflammatory leukocytes. 4. These results suggest that mrIL-5 is a potent inducer of lung inflammation, in terms of increased inflammatory leukocytes and epithelial cells in guinea-pig BALF. Prednisolone, DSCG and ketotifen are effective against mrIL-5-induced pulmonary inflammation, especially the desquamation of bronchial epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596681      PMCID: PMC1908616          DOI: 10.1111/j.1476-5381.1992.tb14204.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

Review 1.  Late-phase airway reaction and inflammation.

Authors:  J Dolovich; F E Hargreave; M Jordana; J Denburg
Journal:  J Allergy Clin Immunol       Date:  1989-02       Impact factor: 10.793

Review 2.  Epithelium-derived relaxing factor(s) and bronchial reactivity.

Authors:  P M Vanhoutte
Journal:  J Allergy Clin Immunol       Date:  1989-05       Impact factor: 10.793

3.  The effect of the selective PAF antagonist BN 52021 on PAF- and antigen-induced bronchial hyper-reactivity and eosinophil accumulation.

Authors:  A J Coyle; S C Urwin; C P Page; C Touvay; B Villain; P Braquet
Journal:  Eur J Pharmacol       Date:  1988-03-22       Impact factor: 4.432

4.  Effect of the selective leukotriene B4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea pigs.

Authors:  I M Richards; R L Griffin; J A Oostveen; J Morris; D G Wishka; C J Dunn
Journal:  Am Rev Respir Dis       Date:  1989-12

Review 5.  The eosinophil and the pathophysiology of asthma.

Authors:  E Frigas; G J Gleich
Journal:  J Allergy Clin Immunol       Date:  1986-04       Impact factor: 10.793

6.  The effect of cromolyn sodium and albuterol on early and late phase bronchoconstriction and airway leukocyte infiltration after allergen challenge of nonanesthetized guinea pigs.

Authors:  P A Hutson; S T Holgate; M K Church
Journal:  Am Rev Respir Dis       Date:  1988-11

7.  Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes.

Authors:  K Takatsu; Y Kikuchi; T Takahashi; T Honjo; M Matsumoto; N Harada; N Yamaguchi; A Tominaga
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

8.  Human eosinophil hematopoiesis studied in vitro by means of murine eosinophil differentiation factor (IL5): production of functionally active eosinophils from normal human bone marrow.

Authors:  E J Clutterbuck; C J Sanderson
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

Review 9.  New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma.

Authors:  P J Barnes
Journal:  J Allergy Clin Immunol       Date:  1989-06       Impact factor: 10.793

10.  Recombinant human interleukin 5 is a selective activator of human eosinophil function.

Authors:  A F Lopez; C J Sanderson; J R Gamble; H D Campbell; I G Young; M A Vadas
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma.

Authors:  E L van Rensen; R G Stirling; J Scheerens; K Staples; P J Sterk; P J Barnes; K F Chung
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 3.  Proinflammatory Pathways in the Pathogenesis of Asthma.

Authors:  R Stokes Peebles; Mark A Aronica
Journal:  Clin Chest Med       Date:  2019-03       Impact factor: 2.878

4.  Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice.

Authors:  A W Mould; K I Matthaei; I G Young; P S Foster
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  Comparative clinical evaluation of ketotifen and montelukast sodium in asthmatic Iraqi patients.

Authors:  Fadyia Y Al-Hamdani
Journal:  Saudi Pharm J       Date:  2010-07-29       Impact factor: 4.330

6.  Inhibition by rapamycin of leukocyte migration and bronchial hyperreactivity induced by injection of Sephadex beads to guinea-pigs.

Authors:  J Nogueira de Francischi; D M Conroy; K Maghni; P Sirois
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo.

Authors:  P D Collins; S Marleau; D A Griffiths-Johnson; P J Jose; T J Williams
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.